Compare Sony Group Corp (SONY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Zimmer Biomet Holdings Inc — how do they compare? Sony Group Corp trades at $24.12 (market cap $136.87B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Sony Group Corp is far larger — about 8.1× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SONY | ZBH | |
|---|---|---|
Market Cap | $136.87B | $16.95B |
Volume | 5,364,503 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $30.26 | $103.98 |
52-Week Low | $19.32 | $79.58 |
Typical Hold Time | 96 Days | 89 Days |
Enterprise Value | $134.77B | $24.02B |
Dividend Yield | 0.66% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $23.95, up 1.83% with bullish technical signals from moving averages. The company shows strong operating cash flow of $2.32T in 2025 and has beaten earnings expectations in two of the last three quarters. Analyst consensus is strongly positive with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and AI-related legal actions against Anthropic.
While Sony demonstrates financial strength with improving cash flow and revenue growth, investors face risks from projected 2026 net losses and competitive pressures. The stock's current valuation appears reasonable with P/E of 20.34, but margin compression and content industry disruption require careful monitoring for sustained shareholder value.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
